Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase <i>Escherichia coli</i> urinary tract infection treatment

Kevin Deemer, Jonathan Grey, Christopher Fronczek, Kerry Marr

Open source

DOI
10.1093/ajhp/zxaa174
Published
2020-08-25
Container
American Journal of Health-System Pharmacy
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ajhp/zxaa174,
  title = {Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase <i>Escherichia coli</i> urinary tract infection treatment},
  author = {Kevin Deemer and Jonathan Grey and Christopher Fronczek and Kerry Marr},
  year = {2020},
  journal = {American Journal of Health-System Pharmacy},
  doi = {10.1093/ajhp/zxaa174},
  url = {https://doi.org/10.1093/ajhp/zxaa174}
}

RIS

TY  - JOUR
TI  - Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase <i>Escherichia coli</i> urinary tract infection treatment
AU  - Kevin Deemer
AU  - Jonathan Grey
AU  - Christopher Fronczek
AU  - Kerry Marr
PY  - 2020
JO  - American Journal of Health-System Pharmacy
DO  - 10.1093/ajhp/zxaa174
UR  - https://doi.org/10.1093/ajhp/zxaa174
ER  - 

APA

Deemer, K., Grey, J., Fronczek, C., & Marr, K. (2020). Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase <i>Escherichia coli</i> urinary tract infection treatment. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaa174

Source records